Evidence map›Paper›PMID 18482025›Full record

ReviewCNS neuroscience & therapeutics2008

Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Richard P Shank, Bruce E Maryanoff

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CNS neuroscience & therapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Inhibitors of Mammalian Aquaporin Water Channels.International journal of molecular sciences · 2019
    Review
  20. Current Status of Antiepileptic Drugs as Preventive Migraine Therapy.Current treatment options in neurology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Richard P ShankResearch & Early Development, Johnson & Johnson Pharmaceutical Research & Development, Spring House, Pennsylvania 19477-0776, USA.
Bruce E Maryanoff

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Topiramate (TPM; TOPAMAX) is a broad-spectrum antiepileptic drug (AED) that is approved in many world markets for preventing or reducing the frequency of epileptic seizures (as monotherapy or adjunctive therapy), and for the prophylaxis of migraine. TPM, a sulfamate derivative of the naturally occurring sugar D-fructose, possesses several pharmacodynamic properties that may contribute to its clinically useful attributes, and to its observed adverse effects. The sulfamate moiety is essential, but not sufficient, for its pharmacodynamic properties. In this review, we discuss the known pharmacodynamic and pharmacokinetic properties of TPM, as well as its various clinically beneficial and adverse effects.

Indexed as

AdultAgedAnticonvulsantsAnti-Obesity AgentsFemaleFructoseHumansHypoglycemic AgentsIon Channel GatingMigraine DisordersNeuroprotective AgentsNeurotransmitter AgentsPregnancyReceptors, PresynapticTopiramateAnticonvulsantsAnti-Obesity AgentsFructoseHypoglycemic AgentsNeuroprotective AgentsNeurotransmitter AgentsReceptors, PresynapticTopiramate

Identifiers

PMID18482025
PMCPMC6494007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.